Every parliamentary written question tabled by Graeme Downie this session, with the full answer and department. Back to the MP page.
Showing 21–23 of 23 · Department of Health and Social Care
How many medicinal approvals used female physiology as a baseline for testing in each of the last five years.
The Medicines and Healthcare products Regulatory Agency does not capture this information in a searchable format, however this information would be available in Public Assessment Reports and summaries of product characteristics, where relevant. These documents are available at the following link:https://products.mhra.gov.uk/
What training is provided to NHS staff to highlight the differences in symptoms of a heart attack between men and women.
Guidance for National Health Service staff is available through the British Heart Foundation, and specific learning sessions are available to support training, with further information on both available, respectively, at the following two links:https://www.bhf.org.uk/informationsupport/conditions/heart-attack/signs-and-symptoms-of-heart-attacks-in-womenhttps://www.chsselearning.org.uk/hearte/15-womens-health/NHS England has been cognisant of gender differences when running public campaigns, and as such has ensured clear messaging on atypical symptoms in women. This has been represented through sharing patient stories within campaign material, highlighting the differences in gender symptoms. Further information on NHS England’s public campaign is available at the following link:https://www.england.nhs.uk/2023/08/nhs-launches-lifesaving-campaign-to-help-people-spot-a-heart-attack/
How much funding the Government has provided for endometriosis research in each of the last five years; and what proportion of Government-funded medicinal research that accounts for.
The Department funds research through the National Institute for Health and Care Research (NIHR). The following table shows how much funding the NIHR has awarded for endometriosis research, as well as that spend as a percentage of total urogynaecology research spend, for each year from 2019/20 to 2023/24:Financial yearSpendProportion of total urogynaecology spend2019/20£493,9458.9%2020/21£554,15110.5%2021/22£973,08916.8%2022/23£1,360,61424.9%2023/24£1,325,32921.9%This information reflects in-year payments to 10 research awards that were active during this time period. It does not reflect the total award value. The total award value for these awards, across their full duration, is £7,714,953.In addition, between 2019/20 and 2023/24, there were 18 awards with relevance to endometriosis active on UK Research and Innovation’s (UKRI) portfolio. These awards had a total value of £8.43 million. The following table shows the in-year expenditure for this research, for each year from 2019/20 to 2023/24:Financial yearIn year spendPercentage of spend versus UKRI research base outturn2019/20£585,662<1%2020/21£683,812<1%2021/22£1,017,417<1%2022/23£1,264,127<1%2023/24£1,589,230<1%The remaining spend is slated for future financial years.